CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

About Science 37 Science 37 Holdings, Inc., a leader in enhancing patient access to clinical trials, announced the final enrollment figures from its 20-month engagement with a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-immune disorders. "Traditional recruitment methods are geographically limited, whereas Science 37 can recruit and enroll patients located anywhere, not just within a certain travel radius of a trial site. This significantly broadens ...